MedTrace Logo

Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer

NCT06992024 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-06-04

No results posted yet for this study

Summary

There are several basic findings in the previous studies: The levels of renin and aldosterone in the blood of cancer patients vary greatly among individuals, and the baseline levels of some patients are relatively higher than others; The elevated levels of renin and aldosterone in the blood are positively correlated with the higher malignancy, drug resistance and progression of gastric cancer; Electroacupuncture stimulation of relevant acupoints can effectively down-regulate the levels of renin and aldosterone in the blood; Electroacupuncture stimulation of relevant acupoints can effectively activate the function of the immune system.

Based on these findings, the present clinical trial aim to evaluated the efficacy and safety of electroacupuncture combined with chemotherapy and PD-1 Antibody for the treatment of specific type of gastric cancer.

Conditions

  • Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer

Interventions

COMBINATION_PRODUCT

Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody

Electroacupuncture (EA) Combined With Paclitaxel Protein-bound (Chemo) and PD-1 Antibody (IO) for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer. Electroacupuncture stimulates specific acupoints（dense-sparse wave，30min）d0, d1, d7, d8 + Paclitaxel Protein-bound (125mg/m2) d1, d8 + PD-1 Antibody (not limited to specific drugs，dosages should be calculated according to corresponding drug instructions) d1, Q3W. If the diseases are well controlled after 6 cycles, maintenance treatment, namely Electroacupuncture stimulates specific acupoints（dense-sparse wave，30min）d0, d1 + PD-1 Antibody (not limited to specific drugs，dosages should be calculated according to corresponding drug instructions) d1, Q3W, will be continually conducted until the diseases progress.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-03-31
Completion
2026-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06992024 on ClinicalTrials.gov